Cambridge scientists target the biology of ageing itself
A Cambridge-based biotechnology company has unveiled a potentially transformative approach to medicine: a drug designed not merely to treat disease, but to slow — and possibly reverse — the ageing process itself.
LinkGevity, a biotech startup (at the Babraham Research Campus) using AI to hunt down the root causes of ageing rather than patching up the symptoms.
They are a rising name in the UK’s life sciences sector, is developing a pioneering therapy that targets necrosis, a destructive cellular process increasingly believed to sit at the heart of ageing and degenerative disease.
Founded by Dr. Carina Kern and Serena Kern-Libera, the Cambridge-based company aims to enter Phase II trials by late 2025.
The drug is not publicly branded yet and it’s currently only referred to as “Anti-Necrotic™” (drug class) or LINK-001 (lead candidate drug)
THE SILENT ENGINE OF AGEING
Necrosis occurs when cells are deprived of oxygen or blood supply, triggering a catastrophic internal collapse. Calcium floods the cell, causing it to rupture and spill its contents into surrounding tissue, damaging healthy cells in a chain reaction of biological decay.
For decades, this process has been viewed as a consequence of disease. Now, scientists believe it may be one of the driving forces behind ageing itself.
The drug aims to target cell necrosis (uncontrolled cell death), and specifically, it aims to block calcium flooding into damaged cells.
LinkGevity’s approach is simple in concept but profound in ambition: stop necrosis, and you may slow the body’s decline at its source.
A DRUG THAT TREATS THE BODY AS A WHOLE
Unlike conventional medicines that target individual illnesses, the experimental therapy is being developed as a holistic treatment — one that works across multiple organ systems.
By preventing calcium overload within vulnerable cells, the drug aims to halt the destructive cascade before it begins, preserving tissue and function.
If successful, the implications could be vast. Conditions such as Alzheimer’s disease, dementia, stroke damage, liver disease and kidney failure — all linked to cellular degeneration — may be slowed, stabilised, or even partially reversed.
FROM LAB BENCH TO HOSPITAL BEDSIDE
The project is being supported by Health Innovation East, which is working to bring the therapy from the laboratory into clinical reality.
Early-stage trials are expected to involve leading NHS institutions, including Addenbrooke’s Hospital in Cambridge and Royal Papworth Hospital. Initial research is likely to focus on kidney disease, with expansion into other age-related conditions to follow.
Researchers describe the work as a crucial step towards translating cutting-edge science into tangible patient benefit.
BACKED BY SPACE-AGE AMBITION
In a striking endorsement of its potential, the research has attracted interest linked to NASA and the UK Space Agency.
Space presents an extreme environment in which ageing is accelerated, offering scientists a unique testing ground for therapies aimed at slowing biological decline. The involvement of space-sector partners underscores the global significance of the work.
A FIRST IN MEDICAL HISTORY?
The drug is still in development, but researchers believe it could become the first treatment specifically designed to target ageing as a biological process rather than a collection of separate diseases.
Early laboratory findings have shown promising reductions in necrotic cell death, fuelling cautious optimism among scientists.
Experts stress that significant testing and regulatory hurdles remain. Yet the direction of travel is clear: medicine may be on the brink of a fundamental shift.
THE FUTURE OF MEDICINE
As populations age and health systems come under increasing strain, the race is on to extend not just lifespan, but healthy years of life.
LinkGevity’s work represents a bold reimagining of how disease is understood and treated.
